title: Recombinant MVA expressing secreted glycoprotein D of BoHV-1 induces systemic and mucosal immunity in animal models.
abstract: Bovine herpesvirus-1 (BoHV-1) infection is distributed worldwide and the development of new tools to fight against this pathogen has become extremely important. In this work a recombinant modified vaccinia virus Ankara (MVA) vector expressing the secreted version of glycoprotein D, MVA-gDs, was obtained and evaluated as a candidate vaccine. First, the correct expression, antigenicity, and N-glycosylation of glycoprotein D were confirmed by molecular techniques. Then MVA-gDs was used as parenteral immunogen in BALB/C mice in which a specific anti-gD humoral immune response was induced and maintained for 7 mo. Two doses of MVA-gDs supplemented with cholera toxin delivered by intranasal immunization induced IgA anti-gD humoral immune responses in nasal and bronchopulmonary washes, as well as IgG anti-gD antibodies in serum samples. In order to evaluate the protection conferred by MVA-gDs immunization, a rabbit BoHV-1 challenge assay was performed. A shorter viral excretion period and a reduction in the number of animals shedding BoHV-1 was observed in the group immunized with recombinant MVA-gDs. In conclusion our data encourage further studies to evaluate MVA-gDs, alone or combined with other immunogens, as a candidate vaccine for BoHV-1.
authors.affiliation: Consejo Nacional de Investigaciones Científicas y Técnicas, Castilla de Correo 25, Buenos Aires, Argentina.
authors.forename: María Florencia
authors.initials: MF
authors.lastname: Ferrer
authors.forename: María Paula
authors.initials: MP
authors.lastname: Del Médico Zajac
authors.forename: Flavia Adriana
authors.initials: FA
authors.lastname: Zanetti
authors.forename: Alejandro Rafael
authors.initials: AR
authors.lastname: Valera
authors.forename: Osvaldo
authors.initials: O
authors.lastname: Zabal
authors.forename: Gabriela
authors.initials: G
authors.lastname: Calamante
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000235:genetics; D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis / Q000097:blood; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D002772:Cholera Toxin / Q000008:administration & dosage / Q000235:genetics; D004195:Disease Models, Animal; D004337:Drug Carriers; D005260:Female; D005822:Genetic Vectors; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control; D022283:Herpesvirus Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000276:immunology; D012376:Rodent Diseases / Q000276:immunology / Q000517:prevention & control; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology*; D017201:Virus Shedding
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D004337:Drug Carriers; D022283:Herpesvirus Vaccines; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D014614:Vaccines, Synthetic; D014764:Viral Proteins; C046998:bovine herpesvirus type-1 glycoproteins; D002772:Cholera Toxin